Clinical and Experimental Pediatrics

The Korean Pediatric Society (대한소아청소년과학회)
권호 표지

Validation of enzyme immunoassay for the quantitative measurement of human IgG antibodies specific for Haemophilus influenzae Type b capsular polysaccharide

Haemophilus influenzae type b 피막 다당질 특이 인간 IgG 항체의 정량적 측정을 위한 enzyme immunoassay의 타당성 연구

  • Kim, Kyung Hyo (Department of Pediatrics, College of Medicine, Ewha Womans University, Center for Vaccine Evaluation and Study, Medical Research Institute, Ewha Womans University) ;
  • Lim, Soo Young (Department of Microbiology, College of Medicine, Ewha Womans University, Center for Vaccine Evaluation and Study, Medical Research Institute, Ewha Womans University)
  • 김경효 (이화여자대학교 의과대학 소아과학교실, 의과학연구소 백신효능연구센터) ;
  • 임수영 (이화여자대학교 의과대학 미생물학교실, 의과학연구소 백신효능연구센터)
  • Received : 2006.09.12
  • Accepted : 2006.10.30
  • Published : 2007.02.15
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose : This study was conducted to validate enzyme immunoassay (EIA) for the quantitative measurement of human IgG antibodies specific for Haemophilus influenzae type b (Hib) capsular polysaccharide. Method : We evaluated specificity, repeatability, intermediate precision, accuracy, lower limit of quantification (LLOQ), and stability to validate standardized EIA for the quantitative measurement of human anti-polyribosylribitol phosphate (PRP) IgG antibodies. Results : The results indicated that this EIA showed specificity to HbO-HA antigen and repeatability and intermediate precision were within acceptance criteria (repeatability: $CV{\leq}15%$, intermediate precision: $CV{\leq}20%$). The EIA-derived results from this laboratory were equivalent to those obtained by the standard radioactive antigen binding assay (RABA) for quantitation of anti-PRP antibodies in the 28 sera. Spiking recovery result was within acceptance criteria ($100{\pm}20%$). The precision and accuracy of samples in LLOQ were from -14.7 to -4.7% in nominal values, which were within acceptance criteria (precision: $CV{\leq}25%$, accuracy: ${\pm}25%$). Freeze-thaw stability and short term temperature stability were within ${\pm}20%$ of acceptance criteria. Conclusions : The EIA which is performed at the Center for Vaccine Evaluation and Study Ewha Medical Research Institute, is an appropriate serologic assay which can be used for quantitation of anti-PRP IgG antibodies in human sera.

목 적: 인체의 항 PRP IgG 항체를 정량적으로 측정하기 위한 방법인 표준화된 효소면역법의 타당성을 연구하는 것이 목적이다. 방 법: 인체의 항 PRP IgG 항체를 정량적으로 측정하기 위한 방법인 표준화된 효소면역법의 타당성을 연구하기 위해 특이성, 반복성, 실험실내 정밀성, 정확성, 최소 정량 한계, 및 안정성을 평가하였다. 결 과: 본 연구에서 사용한 효소면역법은 검사에 사용된 항원(HbO-HA)에 특이성을 보였으며 반복성, 실험실내 정밀성 등의 정밀성은 허용기준(반복성 : $CV{\leq}15%$, 실험실내 정밀성 : $CV{\leq}20%$)을 만족하였다. 정확성은 28개 혈청을 대상으로 한 RABA 정량결과와 효소 면역법 정량결과 비교시험에서 높은 상관계수를 보였고 첨가 회복 검사 결과 허용기준($100{\pm}20%$)을 만족하였다. 최소 정량 한계 시료 정량결과의 정밀성과 정확성은 공칭 양의 -14.7~-4.7%로 모두 허용기준(정밀성 : $CV{\leq}25%$, 정확성 : ${\pm}25%$)을 만족하였다. 안정성 중 냉 해동 안정성과 단기 온도 안정성도 모두 허용기준(${\pm}20%$ 이내)을 만족하였다. 결 론: 이상의 결과로 이화여자대학교 의과학연구소 백신효능연구센터에서 시행한 본 효소 면역법은 혈액 내에 존재하는 항 PRP IgG 항체를 정량적으로 측정하는 시험법으로 적절하였다.

Keywords

References

  1. Wenger JD, Ward JI. Haemophilus influenzae vaccine. In: Plotkin SA, Orenstein WA, editors. Vaccines. 4th ed. Philadelphia: WB Saunders Co, 2004:229-68
  2. American Academy of Pediatrics, Haemophilus influenzae infections. In: Pickering LK, editor. 2003 Red book: Report of the committee on infectious diseases. 26th ed. Elk Grove Village, 2003:293-301
  3. Santosham M, Wolff M, Reid R, Wolff M, Reid R, Hohenboken M, et al. The efficacy in Navajo infants of a conjugate vaccine consisting of Haemophilus influenzae type b polysaccharide and Neisseria meningitidis outermembrane protein complex. N Engl J Med 1991;324:1767-72 https://doi.org/10.1056/NEJM199106203242503
  4. Harrison LH, Tajkowski C, Croll J, Reid R, Hu D, Brenneman G, et al. Postlicensure effectiveness of the Haemophilus influenzae type b polysaccharide-Neisseria meningitidis outer-membrane protein complex conjugate vaccine among Navajo children. J Pediatr 1994;125:571-6 https://doi.org/10.1016/S0022-3476(94)70009-5
  5. Black SB, Shinefield HR Fireman B, Hiatt R, Polen M, Vittinghoff E, The Northern California Kaiser Permanente Vaccine Study Center Pediatrics Group. Efficacy in infancy of oligosaccharide conjugate Haemophilus influenzae type b (HbOC) vaccine in a United States population of 61,080 children. Pediatr Infect Dis J 1991;10:97-104 https://doi.org/10.1097/00006454-199102000-00004
  6. Fritzell B, Plotkin S. Efficacy and safety of a Haemophilus influenzae type b capsular polysaccharide-tetanus protein conjugate vaccine. J Pediatr 1992;121:355-62 https://doi.org/10.1016/S0022-3476(05)81786-X
  7. Booy R, Hodgson S, Carpenter L, Mayon-White RT, Slack MP, Macfarlane JA, et al. Efficacy of Haemophilus influenzae type b conjugate vaccine PRP-T. Lancet 1994;344: 362-6 https://doi.org/10.1016/S0140-6736(94)91400-1
  8. Kayhty H, Peltola H, Karanko V, Makela PH. The protective level of serum antibodies to the capsular polysaccharide of Haemophilus influenzae type b. J Infect Dis 1983;147:1100 https://doi.org/10.1093/infdis/147.6.1100
  9. Anderson P. The protective level of serum antibodies to the capsular polysaccharide of Haemophilus influenzae type b. J Infect Dis 1984;149:1034-5
  10. Phipps DC, West J, Eby R, Koster M, Madore DV, Quataert SA. An ELISA employing a Haemophilus influenzae type b oligosaccharide-human serum albumin conjugate correlates with the radioantigen binding assay. J Immunol Methods 1990;135:121-8 https://doi.org/10.1016/0022-1759(90)90264-V
  11. Mathews DE, Farewell VT. Using and understanding medical statistics, 2nd ed. Basel: Karger AG, 1988:178
  12. Madore DV, Anderson P, Baxter BD, Carlone GM, Edwards KM, Hamilton RG, et al. Interlaboratory study evaluating quantitation of antibodies to Haemophilus influenzae type b polysaccharide by enzyme-linked immunosorbent assay. Clin Diagn Lab Immunol 1996;3:84-8
  13. Kemeny DM, Challacombe SJ. ELISA and other solid phase immunoassays. Theoretical and practical aspects. New York: John Wiley & Sons Ltd. 1988:57-84
  14. Siber GR. Methods for estimating serological correlates of protection. Dev Biol Stand 1997;89:283-96
  15. Robbins JB, Schneerson R, Szu SC. Perspective: hypothesis: serum IgG antibody is sufficient to confer protection against infectious diseases by inactivating the inoculum. J Infect Dis 1995;171:1387-98? https://doi.org/10.1093/infdis/171.6.1387
  16. Fothergill LD, Wright J. Influenzal meningitis: the regulation of age incidence to the bactericidal power of blood against the causal organism. J Immunol 1933;24:273-84
  17. Farr RS. A quantitative immunochemical measure of the primary interaction between I BSA and antibody. J Infect Dis 1958;103:239-62 https://doi.org/10.1093/infdis/103.3.239
  18. Ward JI, Greenberg DP, Anderson PW, Burkart KS, Christenson PD, Gordon LK, et al. Variable quantitation of Haemophilus influenzae type b anticapsular antibody by radioantigen binding assay. J Clin Microbiol 1988;26:72-8
  19. Barra A, Schulz D, Aucouturier P, Preud'homme JL. Measurement of anti-Haemophilus influenzae type b capsular polysaccharide antibodies by ELISA. J Immunol Methods 1988;115:111-7 https://doi.org/10.1016/0022-1759(88)90317-1
  20. Kayhty H, Makela O, Eskola J, Saarinen L, Seppala I. Isotype distribution and bactericidal activity of antibodies after immunization with Haemophilus influenzae type b vaccines at 18-24 months of age. J Infect Dis 1988;158: 973-82 https://doi.org/10.1093/infdis/158.5.973
  21. Wernette CM, Frasch CE, Madore D, Carlone G, Goldblatt D, Plikaytis B, et al. Enzyme-linked immunosorbent assay for quantitation of human antibodies to pneumococcal polysaccharides. Clin Diagn Lab Immunol 2003;10:514-9
  22. Guidance for Industry, Bioanalytical Method Validation. Drug Information Branch (HFD-210) Center for Drug Evaluation and Research (CDER). 2001 May. Available from: http://www.fda.gov/CDER/GUIDANCE/4252fnl.htm
  23. Schmitt HJ, Zepp F, Muschenborn S, Sumenicht G, Schuind A, Beutel K, et al. Immunogenicity and reactogenicity of a Haemophilus influenzae type b tetanus conjugate vaccine when administered separately or mixed with concomitant diphtheria-tetanus-toxoid and acellular pertussis vaccine for primary and for booster immunizations. Eur J Pediatr 1998;157:208-14 https://doi.org/10.1007/s004310050797
  24. Pichichero ME, Latiolais T, Bernstein DI, Hosbach P, Christian E, Vidor E, et al. Vaccine antigen interactions after a combination diphtheria-tetanus toxoid-acellular pertussis/ purified capsular polysaccharide of Haemophilus influenzae type b-tetanus toxoid vaccine in two-, fourand six-month-old infants. Pediatr Infect Dis J 1997;16: 863-70 https://doi.org/10.1097/00006454-199709000-00009
  25. Nolan T, Altmann A, Skeljo M, Streeton C, Schuerman L. Antibody persistence, PRP-specific immune memory, and booster responses in infants immunised with a combination DTPa-HBV-IPV/Hib vaccine. Vaccine 2004;23:14-20 https://doi.org/10.1016/j.vaccine.2004.06.017
  26. Amir J, Liang X, Granoff DM. Variability in the functional activity of vaccines induced antibody to Haemophilus influenzae type b. Pediatr Res 1990;27:358-64 https://doi.org/10.1203/00006450-199004000-00008
  27. Goldblatt D, Vaz AR, Miller E. Antibody avidity as a surrogate marker of successful priming by Haemophilus influenzae type b conjugate vaccines following infant immunization. J Infect Dis 1998;177:1112-5 https://doi.org/10.1086/517407
  28. Romero-Steiner S, Fernandez J, Biltoft C, Wohl ME, Feris J, Balter S, et al. Functional antibody activity elicited by fractional doses of Haemophilus influenzae type b conjugate vaccine (polyribosylribitol phosphate-tetanus toxoid conjugate). Clin Diagn Lab Immunol 2001;8:1115-9